Molecular proximity orchestrates biological function, and blocking existing proximities is an
established therapeutic strategy. By contrast, strengthening or creating neoproximity with …

Targeted protein degradation with molecular glue degraders has arisen as a powerful
therapeutic modality for eliminating classically undruggable disease-causing proteins …

Targeted protein degradation relies on small molecules that induce new protein–protein
interactions between targets and the cellular protein degradation machinery. Most of these …

Targeted protein degradation (TPD) by PROTAC (proteolysis-targeting chimera) and
molecular glue small molecules is an emerging therapeutic strategy. To expand the roster of …

Chemically induced proximity-based targeted protein degradation (TPD) has become a
prominent paradigm in drug discovery. With the clinical benefit demonstrated by certain …

Small molecules that can induce protein degradation by inducing proximity between a
desired target and an E3 ligase have the potential to greatly expand the number of proteins …

Targeted protein degradation with monovalent molecular glue degraders is a powerful
therapeutic modality for eliminating disease causing proteins. However, rational design of …

Unlocking novel E3 ligases for use in heterobifunctional PROTAC degraders is of high
importance to the pharmaceutical industry. Over-reliance on the current suite of ligands used …

Chemoproteomic Covalent Ligand Discovery as the PROTAC-gonist: The Future of Targeted
Degradation Medicines | ACS Central Science Recently Viewedclose modal Pair your accounts …

Small molecule molecular glues can nucleate protein complexes and rewire interactomes.
Molecular glues are widely used as probes for understanding functional proximity at a …